Su­per­nus is mark­ing its ex­pan­sion in­to the Parkin­son’s dis­ease are­na, strik­ing a deal to buy out Adamas Phar­ma­ceu­ti­cals in a deal worth more than $400 mil­lion.

A year af­ter swoop­ing in on its first Parkin­son’s ac­qui­si­tion, the two com­pa­nies an­nounced that they had reached an agree­ment for Su­per­nus to pay up to $9.10 per share in cash as part of the ac­qui­si­tion — close to $450 mil­lion.

“This ac­qui­si­tion rep­re­sents a sig­nif­i­cant step to fur­ther build a strong and di­verse Parkin­son’s dis­ease port­fo­lio, and aligns with our fo­cus of ac­quir­ing val­ue-en­hanc­ing, clin­i­cal­ly-dif­fer­en­ti­at­ed med­i­cines to treat CNS dis­eases,” said Su­per­nus CEO Jack Khat­tar in a state­ment.

This is not the bio­phar­ma’s first for­ay in­to CNS drugs and ther­a­pies. Just last year, the Mary­land phar­ma paid $300 mil­lion to pick up US WorldMeds’ CNS port­fo­lio of Apokyn, My­obloc and Xada­go, along with an apo­mor­phine in­fu­sion pump. Su­per­nus made head­lines ear­li­er this year when the FDA ap­proved the com­pa­ny’s AD­HD non-stim­u­lant treat­ment Qel­bree.

This lat­est ac­qui­si­tion pro­vides Su­per­nus with two more prod­ucts to mar­ket and sell: Go­cov­ri — an FDA-ap­proved treat­ment for off-time and dysk­i­ne­sia in Parkin­son’s pa­tients re­ceiv­ing lev­odopa ther­a­py, along with Parkin­son’s treat­ment Os­molex.

The deal goes down like this: $8.10 per share that must be paid at clos­ing, with two con­tin­gent val­ue rights (CVRs) col­lec­tive­ly worth $1.00 per share in cash. That brings the to­tal val­ue to $9.10 per share in cash.

The first CVR, worth $0.50 per share, is on­ly payable up­on reach­ing $150 mil­lion in an­nu­al (de­fined as four con­sec­u­tive quar­ters) net sales of Adamas’ Go­cov­ri be­tween now and the end of 2024. The sec­ond $0.50 CVR gets paid out once Su­per­nus sees $225 mil­lion in an­nu­al net sales of Go­cov­ri by the end of 2025. For con­text, net sales of Gov­ocri in all of 2020 and the first half of 2021 were $71.2 mil­lion and $37.7 mil­lion, re­spec­tive­ly.

While CVRs can be prof­itable, they can al­so be risky for in­vestors — as Cel­gene in­vestors can at­test to af­ter los­ing their pay­outs at the be­gin­ning of the year, af­ter one of their drugs failed to hit its sched­ule for an ap­proval.

Adamas’ stock price soared af­ter the an­nounce­ment, with $ADMS cross­ing $8 in a 73% jump af­ter the bell on Fri­day.

This new deal is ex­pect­ed to close by ear­ly next year, ac­cord­ing to Su­per­nus.

Fenlai Tan still gets chills thinking about the darkest day of his life.

Three out of eight lung cancer patients who received a tyrosine kinase inhibitor developed by his company, Betta Pharma, died in the span of a month. Tan, the chief medical officer, was summoned to Peking Union Medical College Hospital, where the head of the clinical trial department told him that the trial investigators would be conducting an autopsy to see if the patients had died of the disease — they were all very sick by the time they enrolled — or of interstitial lung disease, a deadly side effect tied to the TKI class that’s been reported in Japan.

After flopping a test in Covid-19 earlier this year, Angion’s lead organ damage drug has now hit the skids again in kidney transplant patients.

Angion and partner Vifor Pharma’s ANG-3777 failed to beat out placebo in terms of improving eGFR, a measure of kidney function, in patients who had received a deceased donor kidney transplant and were at high risk of developing what is known as delayed graft function, according to Phase III results released Tuesday.

The FDA’s Vaccines and Related Biological Products Advisory Committee on Tuesday voted 17-0, with one panelist abstaining, that the benefits of the Pfizer-BioNTech Covid-19 vaccine outweigh the risks for children between the ages of five and 12.

The vote will likely trigger a process that could allow the shots to begin rolling out as early as next week.

The vaccine, which is one-third of the adult Pfizer dose, proved to be about 90% effective in a placebo-controlled trial in which about 1,500 kids in this age range received the vaccine, and only about 12% of those receiving the vaccine had any adverse event. All serious adverse events in the trial were unrelated to the vaccine.